DDInter504 DDInter107
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer .
Desipramine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Desipramine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Desipramine {u} (Compound) resembles {v} (Compound) Amitriptyline
Amitriptyline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Desipramine {u} (Compound) resembles {v} (Compound) Promethazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eplerenone
Eplerenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Desipramine {u} (Compound) resembles {v} (Compound) Aprindine
Aprindine {u} (Compound) resembles {v} (Compound) Fentanyl
Fentanyl {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Desipramine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Desipramine {u} (Compound) resembles {v} (Compound) Epinastine
Epinastine {u} (Compound) resembles {v} (Compound) Amitriptyline
Amitriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Desipramine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Desipramine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Desipramine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Desipramine (Compound) resembles Promethazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Desipramine (Compound) resembles Aprindine (Compound) and Aprindine (Compound) resembles Fentanyl (Compound) and Fentanyl may lead to a major life threatening interaction when taken with Apalutamide
Desipramine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Desipramine (Compound) resembles Epinastine (Compound) and Epinastine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide